12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LX4211 tablet: Additional Phase IIb data

Additional data from a double-blind, U.S. Phase IIb trial in 299 Type II diabetics inadequately controlled on metformin showed that LX4211 plus metformin significantly reduced systolic blood pressure (SBP) by an average of 14 mmHg in patients with high baseline SBP (>=130 mmHg) vs. placebo plus metformin (p=0.002). In patients with normal SBP (<130...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >